Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5490258 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Bevacizumab+MetMAb | EXPERIMENTAL | - |
| Bevacizumab+Placebo | ACTIVE_COMPARATOR | - |
| Pemetrexed+MetMAb | EXPERIMENTAL | - |
| Pemetrexed+Placebo | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle |
| RO5490258 | DRUG | 15 mg/kg iv, Day 1 of each 21-day cycle |
| bevacizumab [Avastin] | DRUG | 15 mg/kg iv, Day 1 of each 21-day cycle |
| cisplatin/carboplatin | DRUG | standard dose iv, Day 1 of each 21-day cycle, 4 cycles |
| paclitaxel | DRUG | 200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles |
| pemetrexed | DRUG | 500 mg/m2, Day 1 of each 21-day cycle |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed Stage IIIB or Stage IV non-squamous non-small cell lung cancer (NSCLC) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * For patients who received prior adjuvant chemotherapy...
RO5490258 is an investigational small molecule being studied for the treatment of Non-Squamous Non-Small Cell Lung Cancer. It is currently in Phase 2 clinical development and is not approved for use. The drug is being evaluated in combination with other therapies to assess its safety and efficacy in this patient population.
RO5490258 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research to evaluate the drug's potential in treating Non-Squamous Non-Small Cell Lung Cancer. As an investigational agent, it is not yet available commercially.
RO5490258 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 study is designed to evaluate the drug's efficacy and safety in patients with Non-Squamous Non-Small Cell Lung Cancer.
RO5490258 is being studied in a completed Phase 2 clinical trial with the identifier NCT01496742. The trial enrolled 259 participants and evaluated the drug in combination with bevacizumab plus platinum and paclitaxel, or with pemetrexed plus platinum, in patients with Non-Squamous Non-Small Cell Lung Cancer.
RO5490258 is also known as onartuzumab, and the two names refer to the same investigational drug. In clinical trials, it is studied under the name onartuzumab, and it is being developed by Roche for the treatment of Non-Squamous Non-Small Cell Lung Cancer.
RO5490258 is a small molecule therapeutic agent. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its potential role in treating Non-Squamous Non-Small Cell Lung Cancer, but its exact mechanism of action remains under study.